Deutsch English Français

Contact

EP1027337

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1027337

EP1027337 - INTEGRIN RECEPTOR ANTAGONISTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 22.10.2004 Database last updated on 25.09.2024
Most recent event Tooltip	22.10.2004	Application deemed to be withdrawn	published on 08.12.2004 [2004/50]
Applicant(s)	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza P.O. Box 7929 Philadelphia Pennsylvania 19103 / US
	[N/P]
Former [2000/33]	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza P.O. Box 7929 Philadelphia Pennsylvania 19103 / US
Inventor(s)	01 / HEERDING, Dirk, A. 1 Mill Creek Lane Malvern, PA 19355 / US
	02 / SAMANEN, James, M. 145 Jug Hollow Road Phoenixville, PA 19460 / US
	[2000/33]
Representative(s)	Valentine, Jill Barbara, et al GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2000/33]	Valentine, Jill Barbara, et al SmithKline Beecham plc Corporate Intellectual Property, Two New Horizons Court Brentford, Middlesex TW8 9EP / GB
Application number, filing date	98944735.4	03.09.1998
	[2000/33]
	WO1998US18379
Priority number, date	US19970057529P	04.09.1997 Original published format: US 57529 P
	US19970063520P	29.10.1997 Original published format: US 63520 P
	[2000/33]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9911626
	Date:	11.03.1999
	Language:	EN
	[1999/10]
	Type:	A1 Application with search report
	No.:	EP1027337
	Date:	16.08.2000
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.03.1999 takes the place of the publication of the European patent application.
	[2000/33]
Search report(s)	International search report - published on:	US	11.03.1999
	(Supplementary) European search report - dispatched on:	EP	20.02.2002
Classification	IPC:	C07D223/20, A61K31/55, C07D413/12	[2002/14]
	CPC:	C07D413/12 (EP); A61P19/10 (EP); A61P35/00 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP)
	Former IPC [2000/33]	C07D223/20, A61K31/55
Designated contracting states	BE, CH, DE, ES, FR, GB, IT, LI, NL [2000/33]
Title	German:	INTEGRIN-REZEPTOR-ANTAGONISTEN	[2000/33]
	English:	INTEGRIN RECEPTOR ANTAGONISTS	[2000/33]
	French:	ANTAGONISTES DES RECEPTEURS D'INTEGRINES	[2000/33]
Entry into regional phase	13.03.2000	National basic fee paid
	13.03.2000	Search fee paid
	13.03.2000	Designation fee(s) paid
	13.03.2000	Examination fee paid
Examination procedure	22.03.1999	Request for preliminary examination filed International Preliminary Examining Authority: US
	13.03.2000	Examination requested [2000/33]
	25.10.2002	Despatch of a communication from the examining division (Time limit: M06)
	05.08.2003	Reply to a communication from the examining division
	26.01.2004	Communication of intention to grant the patent
	08.06.2004	Application deemed to be withdrawn, date of legal effect [2004/50]
	09.07.2004	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2004/50]
Request for further processing for:	05.08.2003	Request for further processing filed
	05.08.2003	Full payment received (date of receipt of payment) Request granted
	21.08.2003	Decision despatched
Fees paid	Renewal fee
	13.09.2000	Renewal fee patent year 03
	03.09.2001	Renewal fee patent year 04
	05.09.2002	Renewal fee patent year 05
	04.09.2003	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]FR1510324 (THOMAE GMBH DR K) [X] 1 * page 1, column 1 - page 2, column 3 *;
		[X]BE632563 (CIBA SA, BÂLE) [X] 1 * starting material (IX) p.8 with the definition of Ph1 and Ph2 of the generic disclosure p.1-2 *;
		[X]EP0419861 (BOEHRINGER INGELHEIM PHARMA [US], et al) [X] 1,2 * claim 1 *;
		[X]WO9701540 (SMITHKLINE BEECHAM CORP [US], et al) [X] 1-10 * the whole document *;
		[PY]WO9830542 (SMITHKLINE BEECHAM CORP [US], et al) [PY] 1-10 * the whole document *;
		[DY]WO9504057 (GENENTECH INC [US], et al) [DY] 1-10 * see abstract, claim 1, formula (I) and (II) *
		[X] - NAGARAJAN, K. ET AL, "Condensed heterotricycles. Potential metabolites of dibenz[b,f][1,4]oxazepine antidepressant, Sintamil", INDIAN J. CHEM. (1974), 12(3), 270-4, XP001055872 [X] 1,2 * page 271; examples 28,29 *
	International search	[A]US5512563 (ALBRIGHT JAY D [US], et al);
		[A]US4551451 (PESTELLINI VITTORIO [IT], et al);
		[A]US3905977 (SIMON EDWARD, et al)

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p